Literature DB >> 7541694

Blockade of mast cell histamine secretion in response to neurotensin by SR 48692, a nonpeptide antagonist of the neurotensin brain receptor.

L A Miller1, D E Cochrane, R E Carraway, R S Feldberg.   

Abstract

1. Pretreatment of rat isolated mast cells with SR 48692, a nonpeptide antagonist of the neurotensin (NT) receptor, prevented histamine secretion in response to NT. 2. This inhibition was rapid in onset (approximately 1 min) and dependent upon the concentration of SR 48692 (IC50 approximately 1-10 nM). 3. SR 48692 (1-1000 nM) did not inhibit histamine secretion elicited by substance P, bradykinin or compound 48/80, or by anti-IgE stimulation of sensitized mast cells. 4. When SR 48692 was injected intradermally (5 pmol in 50 microliters) into anaesthetized rats, 15 min before the intradermal injection of NT, it reduced the effect of NT on vascular permeability. 5. When injected intravenously, SR 48692 attenuated the effects of NT on haematocrit and blood stasis. 6. These results demonstrate that SR 48692 selectively antagonizes the actions of NT on rat isolated mast cells as well as mast cells in vivo. Given the demonstrated specific interaction of SR 48692 with receptors for NT in brain, our results suggest the presence of specific NT receptors on mast cells.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7541694      PMCID： PMC1510300          DOI： 10.1111/j.1476-5381.1995.tb13371.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN： 0007-1188            Impact factor:   8.739


  30 in total

Review 1.  Peptide regulation of mast-cell function.

Authors:  D E Cochrane
Journal:  Prog Med Chem       Date:  1990

Review 2.  G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides.

Authors:  M Mousli; J L Bueb; C Bronner; B Rouot; Y Landry
Journal:  Trends Pharmacol Sci       Date:  1990-09       Impact factor: 14.819

3.  Interaction of substance P, compound 48/80 and mastoparan with the alpha-subunit C-terminus of G protein.

Authors:  M Mousli; C Bronner; J Bockaert; B Rouot; Y Landry
Journal:  Immunol Lett       Date:  1990-09       Impact factor: 3.685

4.  Mast cell activation--a receptor-independent mode of substance P action?

Authors:  H Repke; M Bienert
Journal:  FEBS Lett       Date:  1987-09-14       Impact factor: 4.124

Review 5.  Mast cells, neuropeptides and inflammation.

Authors:  M K Church; M A Lowman; P H Rees; R C Benyon
Journal:  Agents Actions       Date:  1989-04

6.  Structures of histamine-releasing peptides formed by the action of acid proteases on mammalian albumin(s).

Authors:  R E Carraway; D E Cochrane; W Boucher; S P Mitra
Journal:  J Immunol       Date:  1989-09-01       Impact factor: 5.422

7.  Neurotensin binding sites in porcine jejunum: biochemical characterization and intramural localization.

Authors:  V S Seybold; B G Treder; L M Aanonsen; A Parsons; D R Brown
Journal:  Synapse       Date:  1990       Impact factor: 2.562

8.  Activation of Gi-like proteins, a receptor-independent effect of kinins in mast cells.

Authors:  J L Bueb; M Mousli; C Bronner; B Rouot; Y Landry
Journal:  Mol Pharmacol       Date:  1990-12       Impact factor: 4.436

9.  Structure of a biologically active neurotensin-related peptide obtained from pepsin-treated albumin(s).

Authors:  R E Carraway; S P Mitra; D E Cochrane
Journal:  J Biol Chem       Date:  1987-05-05       Impact factor: 5.157

10.  Exocytosis in mast cells by basic secretagogues: evidence for direct activation of GTP-binding proteins.

Authors:  M Aridor; L M Traub; R Sagi-Eisenberg
Journal:  J Cell Biol       Date:  1990-09       Impact factor: 10.539
View more
  8 in total

1.  Antagonism by SR 48692 of mechanical responses to neurotensin in rat intestine.

Authors:  F Mulè; R Serio; A Postorino; T Vetri; F Bonvissuto
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

2.  Corticotropin-releasing hormone induces skin vascular permeability through a neurotensin-dependent process.

Authors:  Jill Donelan; William Boucher; Nikoletta Papadopoulou; Michael Lytinas; Dean Papaliodis; Paul Dobner; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-08       Impact factor: 11.205

3.  HMC-1 human mast cells synthesize neurotensin (NT) precursor, secrete bioactive NT-like peptide(s) and express NT receptor NTS1.

Authors:  David E Cochrane; Robert E Carraway; Kimberly Harrington; Melissa Laudano; Stephen Rawlings; Ross S Feldberg
Journal:  Inflamm Res       Date:  2011-09-17       Impact factor: 4.575

4.  Advanced glycation end products (AGEs) activate mast cells.

Authors:  E Sick; S Brehin; P André; G Coupin; Y Landry; K Takeda; J P Gies
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

5.  Neurotensin is a proinflammatory neuropeptide in colonic inflammation.

Authors:  I Castagliuolo; C C Wang; L Valenick; A Pasha; S Nikulasson; R E Carraway; C Pothoulakis
Journal:  J Clin Invest       Date:  1999-03       Impact factor: 14.808

6.  Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism.

Authors:  Arti B Patel; Irene Tsilioni; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

7.  Neurolysin substrates bradykinin, neurotensin and substance P enhance brain microvascular permeability in a human in vitro model.

Authors:  Abraham J Al-Ahmad; Iqra Pervaiz; Vardan T Karamyan
Journal:  J Neuroendocrinol       Date:  2021-01-28       Impact factor: 3.627

8.  Cannabinoid CB1 Receptors Mediate the Gastroprotective Effect of Neurotensin.

Authors:  Parichehr Hassanzadeh; Elham Arbabi
Journal:  Iran J Basic Med Sci       Date:  2012-05       Impact factor: 2.699
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.